Audit of Best Medical Therapy for Referrals to Vascular Clinic

Slides:



Advertisements
Similar presentations
Peripheral Arterial Disease Mehul Bhatt, MD Interventional Cardiology / Vascular Medicine Athens Heart Center.
Advertisements

Health Promotion in Primary Care
Leadership. Knowledge. Community. Antiplatelet Therapy for the Primary Prevention of Vascular Events Working Group: Alan D. Bell, MD, CCFP and James D.
Preventing Strokes One at a Time Acute Interventions and Management 2009.
National Comparative Audit of Blood Transfusion National Blood Service National Comparative Audit of the Use of Platelets Prepared by John Grant-Casey.
ASCOT ASCOT STUDY. ASCOT INTRODUCTION AND AIMS EXISTING KNOWLEDGE BACKGROUND OF ASCOT STUDY DESIGN (TWO ARMS (BPLA,LLA) METHODOLOGY TREATMENT REGIMES.
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:
Chronic Kidney Disease NICE Guidelines 2008 Dr Jennifer Kuo Dr Naeema Rashid Dr Shamita Das.
Canadian Cardiovascular Society Antiplatelet Guidelines
CVD risk estimation and prevention: An overview of SIGN 97.
Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
Cholesterol quintile (mg/dL)
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Discharge Management of patients with Acute Coronary Syndromes (DMACS) – a quality improvement initiative Feedback A quality improvement initiative in.
Establishing Preventive Cardiology Programs Nathan Wong Nathan Wong.
December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?
Using research to inform and change primary care Professor James Dunbar Greater Green Triangle UDRH
February is Heart & Stroke Awareness Month. Did you know???? Heart Disease and Stroke is Preventable if you know your RISK FACTORS.
VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.
Tina Huang.  Aimed at people aged 40 – 74  Risk assessment and management programme to prevent or delay the onset of diabetes, heart and kidney disease.
10/5/2015. Hypertension GuidelinesDate JNC JNC JNC NICE Guidelines 2011 ESC / ESH Hypertension Guidelines ESC Guideline2007.
Dyslipidemia.  Dyslipidemia is elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high- density lipoprotein level that contributes.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Atherosclerotic Disease of the Carotid Artery Atherosclerosis is a degenerative disease of the arteries resulting in plaques consisting of necrotic cells,
Update on TIA Kath Pasco October  Primary prevention has been effective in fall in incidence of first stroke  Major improvements still required.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.
A Multicentre Audit of Best Medical Therapy for Aneurysm Surveillance Patients P Stather, N Dattani, D Sidloff On Behalf of VERN.
Lipid Lowering Drug Prescribing: ‘patchy’ guideline adherence despite multi-faceted interventions M.E. Cupples 1, Terry Bradley, Chris Hall 1 Dept General.
Date of download: 5/30/2016 Copyright © The American College of Cardiology. All rights reserved. From: Peripheral Artery Disease: Evolving Role of Exercise,
PUTTING PREVENTION FIRST Vascular Checks/ NHS Health Checks.
Brighton and Hove PPMA Preventing Premature Mortality Audit Dr James Simpkin Clinical Facilitator BHPPMA
© Continuing Medical Implementation ® …...bridging the care gap Geriovascular Prevention Optimizing Prevention of Cardiovascular Disease in the Elderly.
Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial
When Using DOPPS Slides. DOPPS Slide Use Guidelines.
Management of Hypertension according to JNC 7
Matching training needs to opportunities
The Plasma Concentrations of Atorvastatin and its Active Metabolites in Relation to the Dose in Stable Coronary Artery Disease Patients at a Tertiary Referral.
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
Integrating Multiple Specialties into Professional Training and Practice: A Vascular Surgeon’s Perspective John J. Ricotta MD FACS Harold Hawfield Chair.
Larissa Registry on CAS and CEA:
Patients with abdominal aortic aneurysm: Are we missing the opportunity for cardiovascular risk reduction?  G.M. Lloyd, MRCS, J.D. Newton, MRCP, M.G.A.
Safi U. Khan MD; John Pamula MD
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Pravastatin in Elderly Individuals at Risk of Vascular Disease
The IDEAL Study Reference
Risk of post-operative stroke in patients with known extra-cranial carotid artery disease undergoing Non-Cardiac Surgery Heart and Vascular.
LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial Marc P. Bonaca, Patrice.
Life after a Cardiovascular Event
The Anglo Scandinavian Cardiac Outcomes Trial
Prevalence and control of cardiovascular risk factors using a German sample – Findings from the STAAB Cohort Study Theresa Tiffe1,3, Götz Gelbrich1,2,
First time a CETP inhibitor shows reduction of serious CV events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Management of Patients following a Myocardial Infarction in the Community Dr Anjali Kay GPST3, Dr Katharine Saxby GP Partner 6-8th October 2016 Introduction.
on behalf of the ASCOT Investigators *Imperial College London, UK
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
Prevalence of statin and beta-blocker use by clinical presentation
Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
RCHC’s Cardiovascular Health Initiative
Ongoing statin therapy at hospitalization for acute myocardial infarction. Learnings for general practitioners. Ghena Shabana Specialist in Family Medicine.
Train-the-Trainer Cases
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Train-the-Trainer Cases
Train-the-Trainer Cases
Low/moderate intensity statins High intensity statins
Low/moderate intensity statins High intensity statins
Presentation transcript:

Audit of Best Medical Therapy for Referrals to Vascular Clinic P Stather, F Muscara, On behalf of the VERN Collaborators* *C Nesbitt, D McCretton, J Shalhoub, A Copland, A Busuttil, R Bootun, S Onida, A Skinner, N Dattani, L Omotolani, R Edmonds, Z Koshnow, A Tsui, M O’Connell, A Duncan, J Blackwell, F Muscara, P Stather, Rozelle Kane, P Brooke, D Sidloff, A Saratzis, D Bosanquet, R Benson, J Pancholi

Background Increased Cardiovascular Risk Worse than a history of MI

Guidelines Aim To determine adherence to cardiovascular risk reduction guidelines in arterial referrals to vascular clinic Antiplatelet Agent Statin Therapy (Atorvastatin 80mg) Smoking Cessation Blood Pressure Control Lifestyle Modification

Methods Results 656 patients Median age 70.9 years Data collected Multicentre audit Promoted through VERN Retrospective review Patients attending vascular clinic Aneurysm, Carotid, Peripheral Arterial Disease 656 patients Median age 70.9 years Reason for Referral Data collected Age Medications Cardiovascular risk factors Smoking status BMT component Percentage Current Smoker 27.4% Antiplatelet 59.2% Statin 61.5% Tested for Diabetes 31.9% BP Check 61.3% Both Antiplatelet and Statin 47.3% Antiplatelet, Statin, Not Smoker 34.3%

Results BMT Component AAA PAD P Value Current Smoker 27.5% 41.4% 0.01 Antiplatelet 57.8% 60.5% NS Statin 56.3% 58.8% Tested for Diabetes 3.8% 14.3% <0.001 BP Check 20.8% 39.4% <0.01 BMT Component Stroke/TIA N=65 Cardiac Hx N=173 Hypertension N=293 Diabetes N=167 No Other Risk Factors N=233 Current Smoker 26.2% 20.8% 24.9% 19.2 35.6% Antiplatelet 72.3% 84.4% 67.6% 77.2% 46.8% Statin 67.7% 76.3% 70.0% 76.0% 37.8% Both Meds 53.8% 55.6% 65.9% 29.2% All 3 40.0% 54.3% 42.0% 53.3% 17.6% BMT Component 0 Risk Factors N=233 1 Risk Factor N=217 2 Risk Factors N=143 3/4 Risk Factors N=63 Current Smoker 35.6% 23.0% 23.6% 20.6% Antiplatelet 46.8% 57.6% 77.8% 88.9% Statin 37.8% 66.4% 70.1% 84.1% Both Meds 29.2% 47.0% 63.2% All 3 17.6% 35.5% 46.5% 63.5%

Conclusions Less than half of patients referred to vascular clinic are on best medical therapy Significant numbers have not had diabetic or BP checks Smoking cessation advice is still necessary The more cardiac risk factors present the better we get at initiating best medical therapy Recommendations National drive to highlight vascular disease as a significant cardiac risk factor Referral protocols reminding General Practitioners to start BMT, check DM and BP and offer smoking cessation

Many thanks to our Collaborators Craig Nesbitt David McCretton Joe Shalhoub Alex Coupland Andrew Busuttil Roshan Bootun Sarah Onida Alex Skinner Lewis Omotolani Nikesh Dattani Ruth Edmonds Znar Koshnow Adrian Tsui Megan O’Connell Andrew Duncan James Blackwell Francesca Muscara Rozelle Kane Philip Stather Peter Brooke David Sidloff Athanasios Saratzis Dave Bosanquet Ruth Benson Wrexham Maelor Hospital Royal Gwent Hospital